Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 59 articles:
HTML format
Text format



Single Articles


    February 2017
  1. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    PubMed     Text format     Abstract available


  2. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    PubMed     Text format     Abstract available


    January 2017
  3. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    PubMed     Text format     Abstract available


  4. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    PubMed     Text format     Abstract available


    December 2016
  5. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    PubMed     Text format     Abstract available


  6. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    PubMed     Text format     Abstract available


    November 2016
  7. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    PubMed     Text format     Abstract available


  8. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    PubMed     Text format     Abstract available


    October 2016
  9. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    PubMed     Text format     Abstract available


  10. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    PubMed     Text format     Abstract available


    September 2016
  11. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    PubMed     Text format     Abstract available


  12. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    PubMed     Text format     Abstract available


  13. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    PubMed     Text format     Abstract available


  14. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    PubMed     Text format     Abstract available


  15. LO CS, Sanii S, Kroeger DR, Milne K, et al
    Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1433.2016.
    PubMed     Text format     Abstract available


    August 2016
  16. LIU JF, Palakurthi S, Zeng Q, Zhou S, et al
    Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
    Clin Cancer Res. 2016 Aug 29. pii: clincanres.1237.2016.
    PubMed     Text format     Abstract available



  17. Correction: Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver.
    Clin Cancer Res. 2016;22:4272.
    PubMed     Text format    


  18. BANDERA EV, Lee VS, Rodriguez-Rodriguez L, Powell B, et al
    RACIAL/ETHNIC DISPARITIES IN OVARIAN CANCER TREATMENT AND SURVIVAL.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1119.2016.
    PubMed     Text format     Abstract available


    July 2016
  19. PERALES-PUCHALT A, Svoronos N, Rutkowski MR, Allegrezza MJ, et al
    FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0492.2016.
    PubMed     Text format     Abstract available


  20. SKATES SJ
    EPIC Early Detection of Ovarian Cancer.
    Clin Cancer Res. 2016 Jul 14. pii: clincanres.1391.2016.
    PubMed     Text format     Abstract available


  21. HORIKAWA N, Abiko K, Matsumura N, Hamanishi J, et al
    Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0387.2016.
    PubMed     Text format     Abstract available


    June 2016
  22. IKEDA Y, Park JH, Miyamoto T, Takamatsu N, et al
    T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0207.2016.
    PubMed     Text format     Abstract available


  23. HOOGSTINS CE, Tummers QR, Gaarenstroom KN, de Kroon CD, et al
    A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.
    Clin Cancer Res. 2016;22:2929-38.
    PubMed     Text format     Abstract available


    April 2016
  24. TIPER IV, Temkin SM, Spiegel S, Goldblum SE, et al
    VEGF potentiates GD3-mediated immune suppression by human ovarian cancer cells.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2518.2015.
    PubMed     Text format     Abstract available


  25. TERRY KL, Schock H, Fortner RT, Husing A, et al
    A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.0316.2016.
    PubMed     Text format     Abstract available


    January 2016
  26. BONITO NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, et al
    Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.1669.2015.
    PubMed     Text format     Abstract available


  27. KROEGER DR, Milne K, Nelson BH
    Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2762.2015.
    PubMed     Text format     Abstract available


    November 2015
  28. LAMBERTS TE, Menke-van der Houven van Oordt CW, Ter Weele EJ, Bensch F, et al
    ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
    Clin Cancer Res. 2015 Nov 20. pii: clincanres.1272.2015.
    PubMed     Text format     Abstract available


  29. SINHA D, Chong L, George J, Schlueter H, et al
    Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients.
    Clin Cancer Res. 2015 Nov 20. pii: clincanres.1931.2015.
    PubMed     Text format     Abstract available


  30. KANG Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, et al
    Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2015 Nov 18. pii: clincanres.1275.2015.
    PubMed     Text format     Abstract available


    October 2015
  31. HEW K, Miller PC, El-Ashry D, Sun J, et al
    MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.0534.2015.
    PubMed     Text format     Abstract available


    September 2015
  32. WOUTERS MC, Komdeur FL, Workel HH, Klip HG, et al
    Treatment regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Sep 18. pii: clincanres.1617.2015.
    PubMed     Text format     Abstract available


    August 2015
  33. ZHONG Q, Peng HL, Zhao X, Zhang L, et al
    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.
    Clin Cancer Res. 2015;21:3807.
    PubMed     Text format    


  34. GONG L, Dong C, Ouyang W
    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.
    Clin Cancer Res. 2015;21:3806.
    PubMed     Text format    


    July 2015
  35. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    PubMed     Text format     Abstract available


  36. KIM G, Ison G, McKee AE, Zhang H, et al
    FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Clin Cancer Res. 2015 Jul 17. pii: clincanres.0887.2015.
    PubMed     Text format     Abstract available


  37. TEWARI KS, Eskander RN, Monk BJ
    Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Clin Cancer Res. 2015 Jul 13. pii: clincanres.0088.2015.
    PubMed     Text format     Abstract available


  38. LIN K, Rubinfeld B, Zhang C, Firestein R, et al
    Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
    Clin Cancer Res. 2015 Jul 8. pii: clincanres.3383.2014.
    PubMed     Text format     Abstract available


  39. JOHNATTY S, Tyrer JP, Kar SP, Beesley J, et al
    Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.0632.2015.
    PubMed     Text format     Abstract available


    June 2015
  40. SINGH AK, Chandra N, Bapat SA
    Evaluation of epigenetic drug targeting of heterogenous tumor cell fractions using potential biomarkers of response in ovarian cancer.
    Clin Cancer Res. 2015 Jun 30. pii: clincanres.0505.2015.
    PubMed     Text format     Abstract available


  41. KOBAYASHI Y, Kashima H, Wu RC, Jung JG, et al
    Mevalonate Pathway Antagonist Inhibits Proliferation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.
    Clin Cancer Res. 2015 Jun 24. pii: clincanres.3368.2014.
    PubMed     Text format     Abstract available


  42. GUO Y, Kenney SR Jr, Cook LS, Adams SF, et al
    A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients.
    Clin Cancer Res. 2015 Jun 12. pii: clincanres.0461.2015.
    PubMed     Text format     Abstract available


    May 2015
  43. DAMELIN M, Bankovich A, Park A, Aguilar J, et al
    Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells To Result In Sustained Tumor Regressions.
    Clin Cancer Res. 2015 May 26. pii: clincanres.0695.2015.
    PubMed     Text format     Abstract available


  44. VATHIPADIEKAL V, Wang XV, Wei W, Waldron L, et al
    Creation of a human Secretome: Novel Composite Library of Human Secreted Proteins: Validation using Ovarian Cancer Gene Expression Data and Virtual Secretome Array.
    Clin Cancer Res. 2015 May 5. pii: clincanres.3173.2014.
    PubMed     Text format     Abstract available


    April 2015
  45. RYNER L, Guan Y, Firestein R, Xiao Y, et al
    Up-Regulation of Periostin and Reactive Stroma is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
    Clin Cancer Res. 2015 Apr 2. pii: clincanres.3111.2014.
    PubMed     Text format     Abstract available


    February 2015
  46. ZSIROS EZ, Duttagupta P, Dangaj D, Li H, et al
    The Ovarian Cancer Chemokine Landscape is Conducive to Homing of Vaccine-primed and CD3/CD28 Costimulated T cells Prepared for Adoptive Therapy.
    Clin Cancer Res. 2015 Feb 23. pii: clincanres.2777.2014.
    PubMed     Text format     Abstract available


  47. SWISHER EM, Norquist BM, Pennington KP, Rendi MH, et al
    DNA repair mutations and outcomes in ovarian cancer-response.
    Clin Cancer Res. 2015;21:659.
    PubMed     Text format    


  48. SOSLOW RA
    DNA repair mutations and outcomes in ovarian cancer-letter.
    Clin Cancer Res. 2015;21:658.
    PubMed     Text format    


    January 2015
  49. GONZALEZ-VILLASANA V, Fuentes-Mattei E, Ivan C, Dalton HJ, et al
    Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer.
    Clin Cancer Res. 2015 Jan 16. pii: clincanres.2279.2014.
    PubMed     Text format     Abstract available


  50. KUMMAR S, Fleming GF, Oza AM, Sullivan DM, et al
    Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer.
    Clin Cancer Res. 2015 Jan 14. pii: clincanres.2565.2014.
    PubMed     Text format     Abstract available


  51. REISS KA, Herman JM, Zahurak M, Brade A, et al
    A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
    Clin Cancer Res. 2015;21:68-76.
    PubMed     Text format     Abstract available


    December 2014
  52. PHAM E, Birrer MJ, Eliasof S, Garmey E, et al
    Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer.
    Clin Cancer Res. 2014 Dec 18. pii: clincanres.2810.2014.
    PubMed     Text format     Abstract available


  53. BOTTSFORD-MILLER J, Choi HJ, Dalton HJ, Stone RL, et al
    Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
    Clin Cancer Res. 2014 Dec 3. pii: clincanres.0870.2014.
    PubMed     Text format     Abstract available


    November 2014
  54. WEN Y, Spannuth Graybill WA, Pevis RA, Hu W, et al
    Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
    Clin Cancer Res. 2014 Nov 21. pii: clincanres.1578.2014.
    PubMed     Text format     Abstract available


  55. CANDIDO DOS REIS FJ, Song H, Goode EL, Cunningham JM, et al
    Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
    Clin Cancer Res. 2014 Nov 14. pii: clincanres.2497.2014.
    PubMed     Text format     Abstract available


  56. RYCAJ K, Plummer JB, Yin B, Li M, et al
    Cytotoxicity of Human Endogenous Retrovirus K Specific T Cells Toward Autologous Ovarian Cancer Cells.
    Clin Cancer Res. 2014 Nov 4. pii: clincanres.0388.2014.
    PubMed     Text format     Abstract available


    October 2014
  57. ZHONG Q, Peng HL, Zhao X, Zhang L, et al
    Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Clin Cancer Res. 2014 Oct 27. pii: clincanres.1816.2014.
    PubMed     Text format     Abstract available


    July 2014
  58. QIN LX, Zhou Q, Bogomolniy F, Villafania L, et al
    Blocking and randomization to improve molecular biomarker discovery.
    Clin Cancer Res. 2014;20:3371-8.
    PubMed     Text format     Abstract available


    February 2014
  59. ROCKALL AG, Avril N, Lam R, Iannone R, et al
    Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume.
    Clin Cancer Res. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: